The CHINOREC trial evaluated the combination of dual immune checkpoint inhibitors (ipilimumab and nivolumab) with neoadjuvant chemoradiotherapy in rectal cancer.
This regimen was found to be safe and feasible without increasing surgical complications or reoperation rates.
Complete pathological response rates were similarly high in both groups but showed no statistically significant improvement with the addition of dual checkpoint blockade.
The study supports further translational research to optimize integration and patient selection for combined immunoradiotherapy.
